Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ≥ 18 years of age;~* Voluntarily signed informed consent;~* Patient is male, or female with negative pregnancy test prior to enrolment;~* Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a detectable plasma HIV-1 RNA);~* Patient must be on stable treatment with HAART for at least 6 months (HAART is defined as an antiretroviral regimen consisting of at least three registered antiretroviral agents\*);~* Mean of all measured CD4+ cell counts during the 6 months prior to the start of HAART must be above or equal to 200 cells/ mm3~* Current CD4+ cell count must be at least 450 cells/ mm3;~* HIV-RNA must be below 50 copies/ mL for the last 6 months prior to inclusion, during at least two measurements (occasional so called 'blips' up to 50 copies/mL are permitted);~* Patient is one of the following: not sexually active, or a heterosexually active female, agreeing to use condoms with her partner from 14 days prior to the first vaccination until 4 months after the last, even though using another method of contraception, and willing to undergo pregnancy tests during screening and prior to each vaccination, or a male, agreeing to use condoms with his partner from the day of the first vaccination until 4 months after the last vaccination.~Exclusion Criteria:~* Treatment with a non-HAART regimen of antiretroviral agents prior to the start of HAART;~* History of a CDC class C event (see Appendix);~* Interruption of HAART during the course of the study which is expected at the time of inclusion;~* History of exposure \<20 years ago to any poxvirus based vaccine;~* Patient is female and has a positive pregnancy test or the wish of pregnancy:~* Active opportunistic infection, or any active infection or malignancy within 30 days prior to screening visit;~* Therapy with immunomodulatory agents, including cytokines (e.g. IL2) and gamma globulin, or cytostatic chemotherapy within 90 days prior to screening visit;~* History of allergy to any vaccine component;~* Use of anti-coagulant medication;~* Use of any investigational drug during the 90 days prior to study entry;~* Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy~* Any other condition which, in the opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine group (Type: EXPERIMENTAL): Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).